We have located links that may give you full text access.
Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization.
Cancer 1996 November 16
BACKGROUND: Positron emission tomography (PET) using F-18-flurodeoxyglucose (18FDG) is an imaging modality allowing direct evaluation of cellular glucose metabolism. The purpose of this study was to examine the role of 18FDG-PET in monitoring chemoembolization therapy of patients with liver metastases from adenocarcinoma.
METHODS: Thirty-four hepatic lesions in 4 patients were evaluated with 18FDG-PET before and 2-3 months after interventional therapy. All patients underwent transcatheter arterial chemoembolization. A total of nine PET studies were performed. Semiquantitative measurement of the metabolic activity of the lesions was performed using the standard uptake value (SUV) of 18FDG. Comparison was performed between sequential PET scans using Student's t test for paired data analysis. The PET findings were also compared with tumor marker levels measured at the time of the PET scans.
RESULTS: Twenty-five of 34 lesions had decreased 18FDG uptake (SUV = 8 +/- 2 vs. 3 +/- 1; P < 0.00001), as expected in successful tumor chemoembolization. These findings were associated with a significant decrease in serum tumor marker levels (86 +/- 4%; P < 0.05) after treatment. However, there were 3 new lesions, and 6 of the 34 lesions demonstrated persistent or increased 18FDG uptake after treatment (SUV = 8 +/- 2 vs. 13 +/- 3; P < 0.05), consistent with the presence of residual viable tumor. These findings led to further interventional therapy in all patients.
CONCLUSIONS: 18FDG-PET allows monitoring of response to treatment with hepatic chemoembolization in patients with liver metastases from adenocarcinoma. PET is a useful diagnostic tool and has the potential to be used to guide further interventional therapy.
METHODS: Thirty-four hepatic lesions in 4 patients were evaluated with 18FDG-PET before and 2-3 months after interventional therapy. All patients underwent transcatheter arterial chemoembolization. A total of nine PET studies were performed. Semiquantitative measurement of the metabolic activity of the lesions was performed using the standard uptake value (SUV) of 18FDG. Comparison was performed between sequential PET scans using Student's t test for paired data analysis. The PET findings were also compared with tumor marker levels measured at the time of the PET scans.
RESULTS: Twenty-five of 34 lesions had decreased 18FDG uptake (SUV = 8 +/- 2 vs. 3 +/- 1; P < 0.00001), as expected in successful tumor chemoembolization. These findings were associated with a significant decrease in serum tumor marker levels (86 +/- 4%; P < 0.05) after treatment. However, there were 3 new lesions, and 6 of the 34 lesions demonstrated persistent or increased 18FDG uptake after treatment (SUV = 8 +/- 2 vs. 13 +/- 3; P < 0.05), consistent with the presence of residual viable tumor. These findings led to further interventional therapy in all patients.
CONCLUSIONS: 18FDG-PET allows monitoring of response to treatment with hepatic chemoembolization in patients with liver metastases from adenocarcinoma. PET is a useful diagnostic tool and has the potential to be used to guide further interventional therapy.
Full text links
Related Resources
Trending Papers
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app